MARKET

FOLD

FOLD

Amicus Therapeut
NASDAQ
9.77
+0.13
+1.35%
After Hours: 9.98 +0.21 +2.15% 18:48 02/14 EST
OPEN
9.68
PREV CLOSE
9.64
HIGH
9.82
LOW
9.65
VOLUME
1.97M
TURNOVER
--
52 WEEK HIGH
14.03
52 WEEK LOW
8.79
MARKET CAP
2.92B
P/E (TTM)
-28.2207
1D
5D
1M
3M
1Y
5Y
1D
Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?
NASDAQ · 15h ago
Weekly Report: what happened at FOLD last week (0210-0214)?
Weekly Report · 19h ago
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
NASDAQ · 4d ago
Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
NASDAQ · 5d ago
TD Cowen Reaffirms Their Buy Rating on Amicus (FOLD)
TipRanks · 02/10 12:15
Weekly Report: what happened at FOLD last week (0203-0207)?
Weekly Report · 02/10 10:03
Morgan Stanley Reaffirms Their Hold Rating on Amicus (FOLD)
TipRanks · 02/06 13:15
Weekly Report: what happened at FOLD last week (0127-0131)?
Weekly Report · 02/03 10:05
More
About FOLD
Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer.

Webull offers Amicus Therapeutics, Inc. stock information, including NASDAQ: FOLD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FOLD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FOLD stock methods without spending real money on the virtual paper trading platform.